Related Experiment Video
Updated: Jun 28, 2026
Lung Rapid Recovery Procurement Combined with Abdominal Normothermic Regional Perfusion in Controlled Donation after Circulatory Death
Published on: August 15, 2022
Case report: severe microscopic polyangiitis successfully treated with extracorporeal membrane oxygenation and
Michael V Di Maria1, Roger Hollister, Jon Kaufman
1Department of Pediatrics, University of Colorado at Denver Health Sciences Center, The Children's Hospital of Denver, Aurora, Colorado, USA.
Abstract:
Severe microscopic polyangiitis can result in acute respiratory failure and renal failure and is commonly treated with mechanical cardiopulmonary support, along with immunosuppression. We report the use of continuous renal replacement therapy and rituximab in a 13-year-old boy with P-antineutrophil cytoplasmic antibody-positive microscopic polyangiitis, resulting in pulmonary hemorrhage and acute renal failure. The patient was treated with high-frequency oscillatory ventilation, extracorporeal membrane oxygenation, and continuous renal replacement therapy, in addition to plasmapheresis, corticosteroids, cyclophosphamide, and rituximab.
Insights
Microscopic polyangiitis can cause severe respiratory and kidney failure. This case study highlights the successful use of continuous renal replacement therapy and rituximab in a pediatric patient with this condition.
Area of Science:
- Nephrology
- Pulmonology
- Pediatric Rheumatology
Background:
- Microscopic polyangiitis (MPA) is a severe systemic vasculitis.
- MPA can lead to critical organ damage, including acute respiratory and renal failure.
- Standard treatment involves immunosuppression and mechanical support.
Observation:
- A 13-year-old boy presented with P-antineutrophil cytoplasmic antibody-positive microscopic polyangiitis.
- The patient experienced severe pulmonary hemorrhage and acute kidney injury.
- Treatment included mechanical cardiopulmonary support and immunosuppressive agents.
Findings:
- Continuous renal replacement therapy (CRRT) was utilized for acute renal failure.
- Rituximab was administered as part of the immunosuppressive regimen.
- The combination therapy led to recovery from critical illness.
Implications:
- This case demonstrates the potential efficacy of CRRT and rituximab in managing severe pediatric MPA.
- Aggressive multi-modal treatment can be life-saving in complex vasculitis cases.
- Further research into optimal treatment strategies for pediatric MPA is warranted.